Cargando…
Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib
The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive metastatic non-small cell lung cancer, is associated with dyslipidemia in over 80% of patients. Clinical trial protocols for the management of lorlatinib-associated dyslipidemia differ from clinica...
Autores principales: | Blais, Normand, Adam, Jean-Philippe, Nguyen, John, Grégoire, Jean C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985771/ https://www.ncbi.nlm.nih.gov/pubmed/36645013 http://dx.doi.org/10.3390/curroncol28010029 |
Ejemplares similares
-
2018 Guidelines for the management of dyslipidemia
por: Rhee, Eun-Jung, et al.
Publicado: (2019) -
2018 Guidelines for the Management of Dyslipidemia in Korea
por: Rhee, Eun-Jung, et al.
Publicado: (2019) -
2022 Saudi Guidelines for the Management of Dyslipidemia
por: AlRahimi, Jamilah, et al.
Publicado: (2023) -
2016 Chinese guidelines for the management of dyslipidemia in adults
Publicado: (2018) -
Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2021)